Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Many potential treatments for Alzheimer's disease target amyloid-β peptides (Aβ), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Aβ-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Aβ levels. Tau reduction also protected both transgenic and nontransgenic mice against excitotoxicity. Thus, tau reduction can block Aβ- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions.

[1]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[2]  J. Lupski.  Genome structural variation and sporadic disease traits , 2006, Nature Genetics.

[3]  Yaakov Stern,et al.  Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[4]  L. Petrucelli,et al.  HSP induction mediates selective clearance of tau phosphorylated at proline‐directed Ser/Thr sites but not KXGS (MARK) sites , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[6]  E. Mandelkow,et al.  Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy , 2006, Journal of Biological Chemistry.

[7]  A M Pittman,et al.  The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. , 2005, Human molecular genetics.

[8]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[9]  Adriana B Ferreira,et al.  The Generation of a 17 kDa Neurotoxic Fragment: An Alternative Mechanism by which Tau Mediates β-Amyloid-Induced Neurodegeneration , 2005, The Journal of Neuroscience.

[10]  Kefei Chen,et al.  Behavioral phenotypes of amyloid‐based genetically modified mouse models of Alzheimer's disease , 2005, Genes, brain, and behavior.

[11]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[12]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[13]  G. Johnson,et al.  Tau phosphorylation: physiological and pathological consequences. , 2005, Biochimica et biophysica acta.

[14]  F. Liu,et al.  Post-translational modifications of tau protein in Alzheimer’s disease , 2005, Journal of Neural Transmission.

[15]  Steven J Novick,et al.  Increased seizure threshold and severity in young transgenic CRND8 mice , 2004, Neuroscience Letters.

[16]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[17]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[18]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[19]  Akihiko Takashima,et al.  Alterations in Glucose Metabolism Induce Hypothermia Leading to Tau Hyperphosphorylation through Differential Inhibition of Kinase and Phosphatase Activities: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[20]  R. Martins,et al.  Amyloid‐β‐induced toxicity of primary neurons is dependent upon differentiation‐associated increases in tau and cyclin‐dependent kinase 5 expression , 2003, Journal of neurochemistry.

[21]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Holsboer.  Corticotropin-releasing hormone modulators and depression. , 2003, Current opinion in investigational drugs.

[23]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[25]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[26]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[27]  M. Hasselmo,et al.  Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Olney,et al.  Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.

[29]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[30]  C. Cotman,et al.  Plasticity of hippocampal circuitry in Alzheimer's disease. , 1985, Science.

[31]  O. Steward,et al.  Behavioral correlates of denervation and reinnervation of the hippocampal formation of the rat: open field activity and cue utilization following bilateral entorhinal cortex lesions , 1977, Brain Research Bulletin.